Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Lavage for Clostridium Difficile Colitis
NCT01630096Phase 4Unknown
- Sponsor
- Ascension
- Start
- Jun 2012
- Primary completion
- Jun 2014
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of polyethylene glycol 3350 + electrolytes in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Ascension. Primary endpoints: Mortality and Length of Stay at 30 days. Status: unknown.
02
Drugs
polyethylene glycol 3350 + electrolytes
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on NCT01630096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01630096.